Clinical Trial: Phase II Study of HLX43 Monotherapy or Combined With Immune Checkpoint Inhibitors in Patients With Locally Advanced, Recurrent, or Metastatic Triple-negative Breast Cancer.

U.S., March 24 -- ClinicalTrials.gov registry received information related to the study (NCT07487519) titled 'Phase II Study of HLX43 Monotherapy or Combined With Immune Checkpoint Inhibitors in Patients With Locally Advanced, Recurrent, or Metastatic Triple-negative Breast Cancer.' on March 17.

Brief Summary: The study is being conducted to explore the reasonable dosage and evaluate the efficacy, safety and tolerability of HLX43 (Anti-PD-L1 ADC) as a monotherapy or in combination with immune checkpoint inhibitors in Subjects with locally advanced, recurrent or metastatic triple-negative breast cancer (TNBC).

Study Start Date: April 25

Study Type: INTERVENTIONAL

Condition: Breast Cancer (Triple Negative Breast Cancer (TNBC))

Intervent...